Tenet Healthcare (NYSE:THC) Receives Outperform Rating from Leerink Partners

Tenet Healthcare (NYSE:THC - Get Free Report)'s stock had its "outperform" rating reaffirmed by stock analysts at Leerink Partners in a report released on Friday, September 18th, Benzinga reports. They currently have a $309.00 price target on the stock. Leerink Partners' price target indicates a potential upside of 18.78% from the stock's previous close.

Several other research analysts have also recently commented on the company. Guggenheim raised their target price on Tenet Healthcare from $242.00 to $283.00 and gave the stock a "buy" rating in a research report on Tuesday, July 28th. Morgan Stanley increased their price objective on Tenet Healthcare from $254.00 to $274.00 and gave the stock an "overweight" rating in a research note on Monday, July 27th. Wall Street Zen upgraded Tenet Healthcare from a "buy" rating to a "strong-buy" rating in a research note on Sunday, August 23rd. Zacks Research upgraded Tenet Healthcare from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 11th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Tenet Healthcare in a research note on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $277.25.

Tenet Healthcare Trading Up 4.2%

NYSE THC traded up $10.60 on Friday, hitting $260.14. 735,067 shares of the company were exchanged, compared to its average volume of 1,181,386. The company's 50 day moving average price is $255.82 and its 200-day moving average price is $213.59. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.41 and a quick ratio of 1.35. The firm has a market capitalization of $20.95 billion, a P/E ratio of 10.03, a price-to-earnings-growth ratio of 1.00 and a beta of 1.23. Tenet Healthcare has a twelve month low of $157.58 and a twelve month high of $283.05.

Tenet Healthcare (NYSE:THC - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The company reported $6.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.26 by $1.86. The firm had revenue of $6.04 billion for the quarter, compared to the consensus estimate of $5.43 billion. Tenet Healthcare had a return on equity of 26.76% and a net margin of 10.27%.The business's revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.02 EPS. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. Analysts predict that Tenet Healthcare will post 21.04 earnings per share for the current fiscal year.

Insider Activity at Tenet Healthcare

In related news, EVP Lisa Y. Foo sold 24,000 shares of the business's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $266.32, for a total transaction of $6,391,680.00. Following the transaction, the executive vice president directly owned 8,053 shares of the company's stock, valued at approximately $2,144,674.96. The trade was a 74.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Saumya Sutaria sold 50,000 shares of the company's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $278.71, for a total value of $13,935,500.00. Following the completion of the transaction, the chief executive officer directly owned 483,564 shares in the company, valued at approximately $134,774,122.44. This represents a 9.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 131,199 shares of company stock worth $35,065,587. Insiders own 0.97% of the company's stock.

Institutional Trading of Tenet Healthcare

Institutional investors have recently modified their holdings of the stock. Norges Bank purchased a new stake in Tenet Healthcare in the fourth quarter worth $248,494,000. Manning & Napier Advisors LLC purchased a new stake in shares of Tenet Healthcare in the second quarter worth $168,761,000. Bank of New York Mellon Corp purchased a new stake in shares of Tenet Healthcare in the second quarter worth $106,342,000. Boston Partners grew its stake in shares of Tenet Healthcare by 15.7% in the fourth quarter. Boston Partners now owns 3,642,136 shares of the company's stock worth $723,804,000 after acquiring an additional 494,581 shares during the last quarter. Finally, Allianz Asset Management GmbH grew its stake in shares of Tenet Healthcare by 78.1% in the fourth quarter. Allianz Asset Management GmbH now owns 868,134 shares of the company's stock worth $172,516,000 after acquiring an additional 380,632 shares during the last quarter. 95.44% of the stock is currently owned by institutional investors.

About Tenet Healthcare

Tenet Healthcare Corporation NYSE: THC is a diversified healthcare services company that owns and operates acute care hospitals and other healthcare facilities in the United States. Its hospitals provide services including emergency care, surgery, cardiovascular care, orthopedics, oncology, women's health and other inpatient and outpatient treatments.

Through its ambulatory business, United Surgical Partners International, Tenet operates and manages ambulatory surgery centers and other outpatient facilities.